Vitamin E Applications in Nonalcoholic Fatty Liver Disease

Nonalcoholic fatty liver disease (NAFLD) affects an estimated quarter of the adult population worldwide and represents a growing public health challenge linked to obesity, insulin resistance and cardiovascular risk. Oxidative stress plays a central role in the initiation and progression of liver fat accumulation and inflammation, creating a rationale for antioxidant interventions. Vitamin E, a family of lipid-soluble antioxidants comprising tocopherols and tocotrienols, has been investigated for its potential to reduce hepatic steatosis, attenuate inflammatory cascades and improve biochemical and histological markers of liver injury. Randomised trials and observational studies have explored both dietary intake and supplemental regimens, with emerging evidence that modest daily doses can yield clinically meaningful reductions in liver enzymes, steatosis scores and inflammatory biomarkers. While questions remain regarding optimal dosage, long-term safety and effects on fibrosis, vitamin E has been integrated into treatment guidelines for selected non-diabetic patients with biopsy-proven steatohepatitis, offering a pragmatic adjunct to lifestyle modification. Current research continues to refine patient selection, explore combination therapies and clarify the role of distinct isoforms in fibrotic processes, underscoring the global significance of vitamin E as an accessible intervention in NAFLD management.

Research from Nature Portfolio

A large cross-sectional analysis using transient elastography has demonstrated that higher dietary and supplemental vitamin E intake is inversely associated with controlled attenuation parameter (CAP) scores, a noninvasive proxy for hepatic fat content. After adjustment for demographic, lifestyle and metabolic confounders, individuals in the highest quartile of dietary intake exhibited significantly lower odds of NAFLD. Supplementary vitamin E use was similarly protective, and total intake showed a marginal but consistent trend towards reduced hepatic steatosis. These findings were robust across sensitivity analyses and highlight the preventive potential of vitamin E, especially in populations without concurrent hyperlipidaemia.

Vitamin E Applications in Nonalcoholic Fatty Liver Disease publication trend

The graph below shows the total number of articles in vitamin e applications in nonalcoholic fatty liver disease across all publications each year (not limited to Nature Index journals).

Technical terms

Nonalcoholic fatty liver disease (NAFLD): A spectrum of liver conditions marked by excessive fat accumulation in the absence of significant alcohol intake.

Metabolic dysfunction-associated steatohepatitis (MASH): A progressive form of NAFLD characterised by hepatic inflammation and injury alongside metabolic disturbances.

Hepatic steatosis: The accumulation of fat droplets within liver cells, indicative of early-stage NAFLD.

Alanine aminotransferase (ALT): An enzyme released into the bloodstream by damaged liver cells, commonly used as a biomarker of hepatocellular injury.

Controlled attenuation parameter (CAP): A noninvasive measure obtained by transient elastography to quantify liver fat content.

References

1. Vitamin E (300 mg) in the treatment of MASH: A multi-center, randomized, double-blind, placebo-controlled study. Cell Reports Medicine (2025).
2. Associations of dietary sources of antioxidant intake and NAFLD: NHANES 2017–2020 and Mendelian randomization. Frontiers in Nutrition (2024).
3. The Effect of Vitamin E Supplementation on Serum Aminotransferases in Non-Alcoholic Fatty Liver Disease (NAFLD): A Systematic Review and Meta-Analysis. Nutrients (2023).
4. Vitamin E intake is inversely associated with NAFLD measured by liver ultrasound transient elastography. Scientific Reports (2024).